Enlivex Ltd. (ENLV) stock
ENLVNasdaqFinance ServicesFiscal year ends December 31
$1.15+0.03 (+2.68%)
Close on Nov 17, 2026Market cap $19.36MP/E 0.0Yield –
Enlivex r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $9.20M, down 13.4% from the year before. Over ten years it grew 1.8% a year on average. The highest annual figure on record is $19.01M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.20M | -13.4% |
| FY2024 | Dec 31, 2024 | $10.62M | -44.1% |
| FY2023 | Dec 31, 2023 | $19.01M | +1.7% |
| FY2022 | Dec 31, 2022 | $18.69M | +45.1% |
| FY2021 | Dec 31, 2021 | $12.88M | +111.6% |
| FY2020 | Dec 31, 2020 | $6.09M | +8.6% |
| FY2019 | Dec 31, 2019 | $5.60M | +39.6% |
| FY2018 | Dec 31, 2018 | $4.01M | +137.3% |
| FY2017 | Dec 31, 2017 | $1.69M | -81.0% |
| FY2016 | Dec 31, 2016 | $8.88M | +15.4% |
| FY2015 | Dec 31, 2015 | $7.69M | +73.2% |
| FY2014 | Dec 31, 2014 | $4.44M | +506.7% |
| FY2013 | Dec 31, 2013 | $732.00K | +422.9% |
| FY2012 | Dec 31, 2012 | $140.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.92M | -28.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.14M | -15.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.00M | +59.0% |
| Q2 FY2023 | Jun 30, 2023 | $5.04M | +623.4% |
| Q2 FY2022 | Jun 30, 2022 | $4.11M | – |
| Q2 FY2021 | Jun 30, 2021 | $2.54M | – |
| Q2 FY2020 | Jun 30, 2020 | $1.26M | – |
| Q2 FY2019 | Jun 30, 2019 | $696.00K | – |
See a number that looks wrong?